CORMEDIX INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.31 USD | +2.31% |
|
+0.57% | +41.22% |
| 04-15 | CorMedix's DefenCath Now Commercially Available For US Inpatient Use | MT |
| 04-15 | CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin) | CI |
| Sales 2024 * | 25.16M 2.01B | Sales 2025 * | 81.93M 6.56B | Capitalization | 292M 23.37B |
|---|---|---|---|---|---|
| Net income 2024 * | -45M -3.6B | Net income 2025 * | 6M 480M | EV / Sales 2024 * | 14.3 x |
| Net Debt 2024 * | 67.4M 5.4B | Net Debt 2025 * | 48.88M 3.91B | EV / Sales 2025 * | 4.16 x |
| P/E ratio 2024 * |
-7.18
x | P/E ratio 2025 * |
-55.9
x | Employees | 83 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on CorMedix Inc.
More recommendations
More press releases
| 1 day | +2.31% | ||
| 1 week | +0.57% | ||
| Current month | +25.24% | ||
| 1 month | +27.64% | ||
| 3 months | +62.39% | ||
| 6 months | +77.00% | ||
| Current year | +41.22% |
1 week
5.00
5.58
1 month
4.057.00
Current year
2.897.00
1 year
2.577.00
3 years
2.578.94
5 years
2.1618.80
10 years
0.8652.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Todisco
CEO | Chief Executive Officer | 48 | 17/03/22 |
Mathew David
DFI | Director of Finance/CFO | 47 | 10/05/20 |
Tushar Mukherjee
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Myron Kaplan
CHM | Chairman | 79 | 26/04/16 |
Steven Lefkowitz
DFI | Director of Finance/CFO | 68 | 14/08/11 |
Alan Dunton
BRD | Director/Board Member | 70 | 28/02/19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 5.31 | +2.31% | 315,424 |
| 25/04/24 | 5.19 | -2.63% | 745,281 |
| 24/04/24 | 5.33 | -2.20% | 422,944 |
| 23/04/24 | 5.45 | +3.22% | 572,806 |
| 22/04/24 | 5.28 | 0.00% | 465,594 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Sector
Pharmaceuticals
Calendar
12/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.31
USD
Average target price
13
USD
Spread / Average Target
+144.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.22% | 292M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- CRMD Stock
